Alvotech (NASDAQ:ALVO) Q2 2022 Earnings Conference Call September 1, 2022 8:00 AM ET

Company Participants

Benedict Stephan - Investor Relations

Robert Wessman - Executive Chairman & Founder

Mark Levick - Chief Executive Officer

Anil Okay - Chief Commercial Officer

Joel Morales - Chief Financial Officer

Ming Li - Chief Strategic Officer

Conference Call Participants

Tybalt Mornan - Morgan Stanley

Karen Marchetti - Northland

Jason Guerra - Bank of America

Benedict Stephan

[Call Started Abruptly] materials and some of our statements that we make today may include forward looking statements. These statements do not ensure future performance and are subject to risks and uncertainties that are outlined in company filings with the Securities and Exchange Commission, and the Nasdaq Iceland Stock Exchange. These risks and uncertainties could cause actual results to differ materially from forward looking statements that are made.

With me on today's call are Robert Wessman, Executive Chairman and Founder of Alvotech, who will give you a quick overview and recap recent strategic milestones. Mark Levick, Chief Executive Officer will cover our portfolio and competitive landscape. Anil Okay, Chief Commercial Officer, who will give a commercial update. Joel Morales, Chief Financial Officer, who will review the financial highlights. And finally, Ming Li, Chief Strategic Officer, who will present our newly published ESG portal and ESG disclosures for 2020 to 2021.

With that, I would like to turn the call over to Robert Wessman, who is Executive Chairman and Founder of Alvotech.

Robert Wessman

Thank you, Benedict. I want to welcome everyone to our second quarter earnings call. This is actually our first started call for Alvotech as a public company. We believe that biosimilar stands to benefit the long term as the healthcare systems are struggling with cost. Biosimilars have the potential to help make health care more sustainable. On June 15, we made those deputes at NASDAQ in New York and on June 23, we listed on NASDAQ personal market in Reykjavik, Iceland. Alvotech is the only companies who are listed in both US, and Iceland, and one of the few to play by similar companies with scale that are publicly traded. Alvotech is a company that has taken 10 years and over a billion dollars to build.

We have been fortunate to make these investments and built our company mean, meanwhile being private. We are very proud of being on having very strong R&D and manufacturing platform and having pipeline of eight biosimilar sub biosimilar candidates with an addressable market over $85 billion. We employ over 800 people around the world with more than 85% focus on R&D, technical operational quality. Our state-of-the-art facility in Reykjavik is designed to support the growth of our pipeline through 2030. Handling end-to-end manufacturing of products substance, product as well as unfinished.